Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus.
Identifieur interne : 001F07 ( Ncbi/Merge ); précédent : 001F06; suivant : 001F08Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus.
Auteurs : Akiko Fukushima [Japon] ; Noboru Fukuda ; Yimu Lai ; Takahiro Ueno ; Mitsuhiko Moriyama ; Fumihiro Taguchi ; Akifumi Iguchi ; Kazushi Shimizu ; Kazumichi KurodaSource :
- Intervirology [ 1423-0100 ] ; 2009.
Descripteurs français
- KwdFr :
- ARN catalytique (génétique), ARN catalytique (pharmacologie), ARN viral (métabolisme), Animaux, Antiviraux (pharmacologie), Données de séquences moléculaires, Lignée cellulaire, Modèles moléculaires, Réplication virale (), Souris, Stabilité de l'ARN, Séquence nucléotidique, Virus de l'hépatite murine (), Virus de l'hépatite murine (génétique), Virus de l'hépatite murine (physiologie), Virus du SRAS (), Virus du SRAS (génétique), Virus du SRAS (physiologie).
- MESH :
- génétique : ARN catalytique, Virus de l'hépatite murine, Virus du SRAS.
- métabolisme : ARN viral.
- pharmacologie : ARN catalytique, Antiviraux.
- physiologie : Virus de l'hépatite murine, Virus du SRAS.
- Animaux, Données de séquences moléculaires, Lignée cellulaire, Modèles moléculaires, Réplication virale, Souris, Stabilité de l'ARN, Séquence nucléotidique, Virus de l'hépatite murine, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Base Sequence, Cell Line, Mice, Models, Molecular, Molecular Sequence Data, Murine hepatitis virus (drug effects), Murine hepatitis virus (genetics), Murine hepatitis virus (physiology), RNA Stability, RNA, Catalytic (genetics), RNA, Catalytic (pharmacology), RNA, Viral (metabolism), SARS Virus (drug effects), SARS Virus (genetics), SARS Virus (physiology), Virus Replication (drug effects).
- MESH :
- chemical , genetics : RNA, Catalytic.
- chemical , metabolism : RNA, Viral.
- chemical , pharmacology : Antiviral Agents, RNA, Catalytic.
- drug effects : Murine hepatitis virus, SARS Virus, Virus Replication.
- genetics : Murine hepatitis virus, SARS Virus.
- physiology : Murine hepatitis virus, SARS Virus.
- Animals, Base Sequence, Cell Line, Mice, Models, Molecular, Molecular Sequence Data, RNA Stability.
Abstract
Severe acute respiratory syndrome (SARS) is a severe pulmonary infectious disease caused by a novel coronavirus. To develop an effective and specific medicine targeting the SARS-coronavirus (CoV), a chimeric DNA-RNA hammerhead ribozyme was designed and synthesized using a sequence homologous with the mouse hepatitis virus (MHV).
DOI: 10.1159/000215946
PubMed: 19420961
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001910
- to stream PubMed, to step Curation: 001910
- to stream PubMed, to step Checkpoint: 001901
Links to Exploration step
pubmed:19420961Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus.</title>
<author><name sortKey="Fukushima, Akiko" sort="Fukushima, Akiko" uniqKey="Fukushima A" first="Akiko" last="Fukushima">Akiko Fukushima</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fukuda, Noboru" sort="Fukuda, Noboru" uniqKey="Fukuda N" first="Noboru" last="Fukuda">Noboru Fukuda</name>
</author>
<author><name sortKey="Lai, Yimu" sort="Lai, Yimu" uniqKey="Lai Y" first="Yimu" last="Lai">Yimu Lai</name>
</author>
<author><name sortKey="Ueno, Takahiro" sort="Ueno, Takahiro" uniqKey="Ueno T" first="Takahiro" last="Ueno">Takahiro Ueno</name>
</author>
<author><name sortKey="Moriyama, Mitsuhiko" sort="Moriyama, Mitsuhiko" uniqKey="Moriyama M" first="Mitsuhiko" last="Moriyama">Mitsuhiko Moriyama</name>
</author>
<author><name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name>
</author>
<author><name sortKey="Iguchi, Akifumi" sort="Iguchi, Akifumi" uniqKey="Iguchi A" first="Akifumi" last="Iguchi">Akifumi Iguchi</name>
</author>
<author><name sortKey="Shimizu, Kazushi" sort="Shimizu, Kazushi" uniqKey="Shimizu K" first="Kazushi" last="Shimizu">Kazushi Shimizu</name>
</author>
<author><name sortKey="Kuroda, Kazumichi" sort="Kuroda, Kazumichi" uniqKey="Kuroda K" first="Kazumichi" last="Kuroda">Kazumichi Kuroda</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19420961</idno>
<idno type="pmid">19420961</idno>
<idno type="doi">10.1159/000215946</idno>
<idno type="wicri:Area/PubMed/Corpus">001910</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001910</idno>
<idno type="wicri:Area/PubMed/Curation">001910</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001910</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001901</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001901</idno>
<idno type="wicri:Area/Ncbi/Merge">001F07</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus.</title>
<author><name sortKey="Fukushima, Akiko" sort="Fukushima, Akiko" uniqKey="Fukushima A" first="Akiko" last="Fukushima">Akiko Fukushima</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fukuda, Noboru" sort="Fukuda, Noboru" uniqKey="Fukuda N" first="Noboru" last="Fukuda">Noboru Fukuda</name>
</author>
<author><name sortKey="Lai, Yimu" sort="Lai, Yimu" uniqKey="Lai Y" first="Yimu" last="Lai">Yimu Lai</name>
</author>
<author><name sortKey="Ueno, Takahiro" sort="Ueno, Takahiro" uniqKey="Ueno T" first="Takahiro" last="Ueno">Takahiro Ueno</name>
</author>
<author><name sortKey="Moriyama, Mitsuhiko" sort="Moriyama, Mitsuhiko" uniqKey="Moriyama M" first="Mitsuhiko" last="Moriyama">Mitsuhiko Moriyama</name>
</author>
<author><name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name>
</author>
<author><name sortKey="Iguchi, Akifumi" sort="Iguchi, Akifumi" uniqKey="Iguchi A" first="Akifumi" last="Iguchi">Akifumi Iguchi</name>
</author>
<author><name sortKey="Shimizu, Kazushi" sort="Shimizu, Kazushi" uniqKey="Shimizu K" first="Kazushi" last="Shimizu">Kazushi Shimizu</name>
</author>
<author><name sortKey="Kuroda, Kazumichi" sort="Kuroda, Kazumichi" uniqKey="Kuroda K" first="Kazumichi" last="Kuroda">Kazumichi Kuroda</name>
</author>
</analytic>
<series><title level="j">Intervirology</title>
<idno type="eISSN">1423-0100</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Base Sequence</term>
<term>Cell Line</term>
<term>Mice</term>
<term>Models, Molecular</term>
<term>Molecular Sequence Data</term>
<term>Murine hepatitis virus (drug effects)</term>
<term>Murine hepatitis virus (genetics)</term>
<term>Murine hepatitis virus (physiology)</term>
<term>RNA Stability</term>
<term>RNA, Catalytic (genetics)</term>
<term>RNA, Catalytic (pharmacology)</term>
<term>RNA, Viral (metabolism)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (genetics)</term>
<term>SARS Virus (physiology)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN catalytique (génétique)</term>
<term>ARN catalytique (pharmacologie)</term>
<term>ARN viral (métabolisme)</term>
<term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Données de séquences moléculaires</term>
<term>Lignée cellulaire</term>
<term>Modèles moléculaires</term>
<term>Réplication virale ()</term>
<term>Souris</term>
<term>Stabilité de l'ARN</term>
<term>Séquence nucléotidique</term>
<term>Virus de l'hépatite murine ()</term>
<term>Virus de l'hépatite murine (génétique)</term>
<term>Virus de l'hépatite murine (physiologie)</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (génétique)</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>RNA, Catalytic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>RNA, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>RNA, Catalytic</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Murine hepatitis virus</term>
<term>SARS Virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Murine hepatitis virus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN catalytique</term>
<term>Virus de l'hépatite murine</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>ARN viral</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>ARN catalytique</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus de l'hépatite murine</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Murine hepatitis virus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Base Sequence</term>
<term>Cell Line</term>
<term>Mice</term>
<term>Models, Molecular</term>
<term>Molecular Sequence Data</term>
<term>RNA Stability</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Données de séquences moléculaires</term>
<term>Lignée cellulaire</term>
<term>Modèles moléculaires</term>
<term>Réplication virale</term>
<term>Souris</term>
<term>Stabilité de l'ARN</term>
<term>Séquence nucléotidique</term>
<term>Virus de l'hépatite murine</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a severe pulmonary infectious disease caused by a novel coronavirus. To develop an effective and specific medicine targeting the SARS-coronavirus (CoV), a chimeric DNA-RNA hammerhead ribozyme was designed and synthesized using a sequence homologous with the mouse hepatitis virus (MHV).</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19420961</PMID>
<DateCompleted><Year>2009</Year>
<Month>07</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2009</Year>
<Month>05</Month>
<Day>29</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0100</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>52</Volume>
<Issue>2</Issue>
<PubDate><Year>2009</Year>
</PubDate>
</JournalIssue>
<Title>Intervirology</Title>
<ISOAbbreviation>Intervirology</ISOAbbreviation>
</Journal>
<ArticleTitle>Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus.</ArticleTitle>
<Pagination><MedlinePgn>92-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1159/000215946</ELocationID>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Severe acute respiratory syndrome (SARS) is a severe pulmonary infectious disease caused by a novel coronavirus. To develop an effective and specific medicine targeting the SARS-coronavirus (CoV), a chimeric DNA-RNA hammerhead ribozyme was designed and synthesized using a sequence homologous with the mouse hepatitis virus (MHV).</AbstractText>
<AbstractText Label="METHOD" NlmCategory="METHODS">Chimeric DNA-RNA hammerhead ribozyme targeting MHV and SARS-CoV were designed and synthesized.To confirm its activity, in vitro cleavage reactions were performed with the synthesized ribozyme. Effects of the chimeric ribozyme were evaluated on multiplication of MHV. Effects of the chimeric ribozyme on expression of SARS-CoV were evaluated in cultured 3T3 cells.</AbstractText>
<AbstractText Label="RESULT" NlmCategory="RESULTS">The synthetic ribozyme cleaved the synthetic target MHV and SARS-CoV RNA into fragments of predicted length. The chimeric DNA-RNA hammerhead ribozyme targeting SARS-CoV significantly inhibited multiplication of MHV in DBT cells by about 60%. The chimeric DNA-RNA hammerhead ribozyme targeting SARS-CoV significantly inhibited the expression of SARS-CoV RNA in 3T3 cells transfected with the recombinant plasmid. The chimeric DNA-RNA ribozyme targeting SARS-CoV significantly inhibited MHV viral activity and expression of recombinant SARS RNA in vitro.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings indicate that the synthetic chimeric DNA-RNA ribozyme could provide a feasible treatment for SARS.</AbstractText>
<CopyrightInformation>Copyright (c) 2009 S. Karger AG, Basel.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fukushima</LastName>
<ForeName>Akiko</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fukuda</LastName>
<ForeName>Noboru</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lai</LastName>
<ForeName>Yimu</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ueno</LastName>
<ForeName>Takahiro</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Moriyama</LastName>
<ForeName>Mitsuhiko</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Taguchi</LastName>
<ForeName>Fumihiro</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Iguchi</LastName>
<ForeName>Akifumi</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Shimizu</LastName>
<ForeName>Kazushi</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kuroda</LastName>
<ForeName>Kazumichi</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2009</Year>
<Month>05</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Intervirology</MedlineTA>
<NlmUniqueID>0364265</NlmUniqueID>
<ISSNLinking>0300-5526</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016337">RNA, Catalytic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C427204">hammerhead ribozyme</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006517" MajorTopicYN="N">Murine hepatitis virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020871" MajorTopicYN="N">RNA Stability</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016337" MajorTopicYN="N">RNA, Catalytic</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year>
<Month>11</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2009</Year>
<Month>02</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>5</Month>
<Day>8</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>5</Month>
<Day>8</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>7</Month>
<Day>3</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19420961</ArticleId>
<ArticleId IdType="pii">000215946</ArticleId>
<ArticleId IdType="doi">10.1159/000215946</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Japon</li>
</country>
<region><li>Région de Kantō</li>
</region>
<settlement><li>Tokyo</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Fukuda, Noboru" sort="Fukuda, Noboru" uniqKey="Fukuda N" first="Noboru" last="Fukuda">Noboru Fukuda</name>
<name sortKey="Iguchi, Akifumi" sort="Iguchi, Akifumi" uniqKey="Iguchi A" first="Akifumi" last="Iguchi">Akifumi Iguchi</name>
<name sortKey="Kuroda, Kazumichi" sort="Kuroda, Kazumichi" uniqKey="Kuroda K" first="Kazumichi" last="Kuroda">Kazumichi Kuroda</name>
<name sortKey="Lai, Yimu" sort="Lai, Yimu" uniqKey="Lai Y" first="Yimu" last="Lai">Yimu Lai</name>
<name sortKey="Moriyama, Mitsuhiko" sort="Moriyama, Mitsuhiko" uniqKey="Moriyama M" first="Mitsuhiko" last="Moriyama">Mitsuhiko Moriyama</name>
<name sortKey="Shimizu, Kazushi" sort="Shimizu, Kazushi" uniqKey="Shimizu K" first="Kazushi" last="Shimizu">Kazushi Shimizu</name>
<name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name>
<name sortKey="Ueno, Takahiro" sort="Ueno, Takahiro" uniqKey="Ueno T" first="Takahiro" last="Ueno">Takahiro Ueno</name>
</noCountry>
<country name="Japon"><region name="Région de Kantō"><name sortKey="Fukushima, Akiko" sort="Fukushima, Akiko" uniqKey="Fukushima A" first="Akiko" last="Fukushima">Akiko Fukushima</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F07 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001F07 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:19420961 |texte= Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:19420961" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |